Negatively charged AuNP modified with monoclonal antibody against novel tumor antigen FAT1 for tumor targeting

Li Fan, Susanna Campagnoli, Hong Wu, Alberto Grandi, Matteo Parri, Elisa De Camilli, Guido Grandi, Giuseppe Viale, Piero Pileri, Renata Grifantini, Chaojun Song, Boquan Jin

Research output: Contribution to journalArticlepeer-review


Background: Herein, we demonstrated the use of a newly generated anti FAT1 antibody (clone mAB198.3) for intracellular delivery of anionic gold NPs, to form active targeting Au nanoparticles with high payload characteristics. Methods: In vitro characterizations were determined by DLS, confocal microscopy, TEM, western blot, MALDI-TOF MS/MS analysis, MTT, ICP-MS and flow cytometry analysis. In vivo targeting efficacy was investigated by in vivo bio-imaging study and ICP-MS. Results: The specificity of the FAT1 recognition in colon cancer was confirmed by pre-adsorbing mAb198.3, adsorption dramatically abolished the antibody reactivity on colon cancer, thus confirming the binding specificity. The DLS size distribution profile of the AuCOOH, AuCOOH(Cy5)- mAb198.3, AuCOOH(Cy5)-isotype has showed that the modified gold nanoparticles are well dispersed in water, PBS buffer and cell culture medium with 10 % FBS. By TEM measurement, the size of Au nanoparticles with spherical morphology is about 10-20 nm. AuCOOH-198.3 NPs were stable in an acidic environment, as well as in PBS buffer, cell culture media and media with 10 % serum. MTT results revealed that Au nanoparticles have well biocompatibility. TEM results indicated that conjugation of mAb198.3 on Au nanoparticles can be an effective delivery vehicle for negatively charged gold nanoparticles and increased its intracellular transport. It was also demonstrated by confocal microscopy that AuCOOH(Cy5)-mAb198.3 could attach to the cell membrane in very short time, then gradually delivered into cells. After 4 h incubation, almost all AuCOOH(Cy5)-mAb198.3 have been uptaken into or surrounding the cytoplasm and nucleus. In vivo results showed that only about 20 % of AuCOOH accumulated in tumor site due to EPR effect, while nearly 90 % of AuCOOH-mAb198.3 was found in tumor, providing sufficient evidence for receptor-specific targeting by mAb198.3. Conclusion: According to in vitro and in vivo research results, the intracellular uptake of negatively charged AuCOOH-mAB198.3 particles is enhanced to a greater extent. Thus, AuCOOH-mAb198.3 holds significant potential to improve the treatment of cancer.

Original languageEnglish
Article number103
JournalJournal of Experimental and Clinical Cancer Research
Issue number1
Publication statusPublished - Sep 15 2015


  • FAT1
  • mAb198.3
  • Negative gold nanoparticles
  • Tumor targeting

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Negatively charged AuNP modified with monoclonal antibody against novel tumor antigen FAT1 for tumor targeting'. Together they form a unique fingerprint.

Cite this